Search Results 531-540 of 25619 for crohns disease

  1. Inflammatory bowel disease (IBD) - Doctors and departments - Mayo Clinic

    Long-lasting diarrhea and belly pain could be caused by inflammatory bowel disease, also called IBD. Learn about IBD causes, diagnosis and treatment.

  2. Phase IIa Study Evaluating AZD7798 in Crohn's Disease (AMALTHEA) - Mayo Clinic

    The purpose of this study is to evaluate the efficacy and safety of AZD7798 in participants with moderate to severe Crohn's disease. Participation eligibility.

  3. Inflammatory bowel disease (IBD) - Doctors and departments - Mayo Clinic

    Long-lasting diarrhea and belly pain could be caused by inflammatory bowel disease, also called IBD. Learn about IBD causes, diagnosis and treatment.

  4. Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects with Moderate to Severe Crohn's Disease - Mayo Clinic

    This study will evaluate the efficacy and safety of two adalimumab induction regimens in subjects with moderately to severely active Crohn's disease and ...

  5. Inflammatory bowel disease (IBD) - Doctors and departments - Mayo Clinic

    Long-lasting diarrhea and belly pain could be caused by inflammatory bowel disease, also called IBD. Learn about IBD causes, diagnosis and treatment.

  6. Inflammatory bowel disease (IBD) - Doctors and departments - Mayo Clinic

    Long-lasting diarrhea and belly pain could be caused by inflammatory bowel disease, also called IBD. Learn about IBD causes, diagnosis and treatment.

  7. Diarrhea - Mayo Clinic

    Chronic diarrhea can indicate a serious disorder, such as ulcerative colitis or Crohn's disease, or a less serious condition, such as irritable bowel syndrome.

  8. Inflammatory bowel disease biobank research update - Mayo Clinic

    Researchers from Mayo Clinic's inflammatory bowel disease (IBD) biobank are hopeful that serologic and genetic markers will help them develop therapeutic ...

  9. Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) - Mayo Clinic

    Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult ...

  10. A Study to Evaluate the Patterns of Use of Biological Agents and Risk Factors for Discontinuation of Agents in Pediatric Crohn’s Disease (CD) and Ulcerative Colitis (UC) within the Pediatric Population - Mayo Clinic

    ... Crohn's Disease (CD) and Ulcerative Colitis (UC) within the Pediatric Population ... Participant eligibility includes age, gender, type and stage of disease, and ...